➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Express Scripts
Medtronic
Boehringer Ingelheim

Last Updated: July 30, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,775,953


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,775,953 protect, and when does it expire?

Patent 9,775,953 protects OZEMPIC and SAXENDA and is included in two NDAs.

Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ten patent family members in nine countries.

Summary for Patent: 9,775,953
Title:Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Abstract: A mechanism for preventing setting of a dose, which exceeds the amount of a medicament in a reservoir in an injection device. The device can contain a threaded piston rod, a limiter and a driver. The three elements can be arranged such that during dose setting, the limiter is moved towards an end-of-content position, wherein dose setting is limited. The invention contains an accumulative and a non-accumulative embodiment. The invention further relates to a mechanism for preventing ejection of a dose exceeding the set dose.
Inventor(s): Enggaard; Christian Peter (Vejby, DK), Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsvaerd, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:14/550,085
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 9,775,953

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-001 Dec 5, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-002 Apr 9, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Novo SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,775,953

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05016291Jul 27, 2005

International Family Members for US Patent 9,775,953

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 499962 ⤷  Free Forever Trial
China 101227943 ⤷  Free Forever Trial
Germany 602006020453 ⤷  Free Forever Trial
Denmark 1909870 ⤷  Free Forever Trial
European Patent Office 1909870 ⤷  Free Forever Trial
Spain 2361563 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKinsey
Boehringer Ingelheim
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.